Identification of drivers of breast cancer invasion by secretome analysis: insight into CTGF signaling

2020 | journal article. A publication with affiliation to the University of Göttingen.

Jump to:Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Identification of drivers of breast cancer invasion by secretome analysis: insight into CTGF signaling​
Hellinger, J. W.; Schömel, F.; Buse, J. V.; Lenz, C. ; Bauerschmitz, G. ; Emons, G.   & Gründker, C. ​ (2020) 
Scientific Reports10(1).​ DOI: https://doi.org/10.1038/s41598-020-74838-8 

Documents & Media

s41598-020-74838-8.pdf6.44 MBAdobe PDF

License

Published Version

Usage license

Details

Authors
Hellinger, Johanna W.; Schömel, Franziska; Buse, Judith V.; Lenz, Christof ; Bauerschmitz, Gerd ; Emons, Günter ; Gründker, Carsten 
Abstract
Abstract An altered consistency of tumor microenvironment facilitates the progression of the tumor towards metastasis. Here we combine data from secretome and proteome analysis using mass spectrometry with microarray data from mesenchymal transformed breast cancer cells (MCF-7-EMT) to elucidate the drivers of epithelial-mesenchymal transition (EMT) and cell invasion. Suppression of connective tissue growth factor (CTGF) reduced invasion in 2D and 3D invasion assays and expression of transforming growth factor-beta-induced protein ig-h3 (TGFBI), Zinc finger E-box-binding homeobox 1 (ZEB1) and lysyl oxidase (LOX), while the adhesion of cell-extracellular matrix (ECM) in mesenchymal transformed breast cancer cells is increased. In contrast, an enhanced expression of CTGF leads to an increased 3D invasion, expression of fibronectin 1 (FN1), secreted protein acidic and cysteine rich (SPARC) and CD44 and a reduced cell ECM adhesion. Gonadotropin-releasing hormone (GnRH) agonist Triptorelin reduces CTGF expression in a Ras homolog family member A (RhoA)-dependent manner. Our results suggest that CTGF drives breast cancer cell invasion in vitro and therefore could be an attractive therapeutic target for drug development to prevent the spread of breast cancer.
Issue Date
2020
Journal
Scientific Reports 
eISSN
2045-2322
Language
English
Sponsor
Open-Access-Publikationsfonds 2021

Reference

Citations


Social Media